



MEDICAL POLICY STATEMENT

Arkansas PASSE

Policy Name & Number	Date Effective
Sacroiliac Joint Procedures-AR PASSE-MM-1507	03/01/2026
Policy Type	
MEDICAL	

Medical Policy Statement prepared by CareSource and its affiliates are derived from literature based on and supported by clinical guidelines, nationally recognized utilization and technology assessment guidelines, other medical management industry standards, and published MCO clinical policy guidelines. Medically necessary services include, but are not limited to, those health care services or supplies that are proper and necessary for the diagnosis or treatment of disease, illness, or injury and without which the patient can be expected to suffer prolonged, increased or new morbidity, impairment of function, dysfunction of a body organ or part, or significant pain and discomfort. These services meet the standards of good medical practice in the local area, are the lowest cost alternative, and are not provided mainly for the convenience of the member or provider. Medically necessary services also include those services defined in any Evidence of Coverage documents, Medical Policy Statements, Provider Manuals, Member Handbooks, and/or other policies and procedures.

Medical Policy Statements prepared by CareSource and its affiliates do not ensure an authorization or payment of services. Please refer to the plan contract (often referred to as the Evidence of Coverage) for the service(s) referenced in the Medical Policy Statement. If there is a conflict between the Medical Policy Statement and the plan contract (i.e., Evidence of Coverage), then the plan contract (i.e., Evidence of Coverage) will be the controlling document used to make the determination. According to the rules of Mental Health Parity Addiction Equity Act (MHPAEA), coverage for the diagnosis and treatment of a behavioral health disorder will not be subject to any limitations that are less favorable than the limitations that apply to medical conditions as covered under this policy.

Table of Contents

A.	Subject	2
B.	Background	2
C.	Definitions	2
D.	Policy	3
E.	Conditions of Coverage	5
F.	Related Policies/Rules	5
G.	Review/Revision History	5
H.	References	5

A. Subject

Sacroiliac Joint Procedures

B. Background

Nearly 84% of adults experience back pain during their lifetime. Long-term outcomes are largely favorable for most patients, but a small percentage of patients' symptoms are persistent. Persistent pain is categorized as subacute when lasting between four and twelve weeks, and chronic when persisting for at least three months.

Up to 10% to 30% of patients with persistent low back pain may have a component of pain related to sacroiliac joints (SIJ). Comprehensive pain management care plans are most effective in managing a patient's chronic pain. These plans focus on a person-centered approach and incorporate conservative treatment with other modalities. These multidisciplinary treatments include promoting patient self-management and aim to reduce the impact of pain on a patient's daily life, even if the pain cannot be relieved completely. In addition to conservative therapy, additional treatment options may include nonpharmacologic or pharmacologic treatments, nonsurgical interventions, and surgical interventions. Interventional procedures for the management of pain unresponsive to conservative treatment should be provided only by physicians qualified to deliver these health services.

Sacroiliac joint injections using local anesthetic and/or corticosteroid medication have been shown to be effective for diagnostic purposes but provide limited short-term relief from pain resulting from SIJ dysfunction. Long-term use has not been adequately studied to establish standards of care. Radiofrequency ablation (RFA) is another treatment method, which uses heat to destroy nerves. RFA for the treatment of low back pain has inconsistent results in the peer-reviewed medical literature with limited follow-up. However, clinical experience suggests that some patients obtain more significant relief from these procedures, making it reasonable to offer SIJ injections and/or RFA when conservative management has failed.

C. Definitions

- **Conservative Therapy** – A multimodal plan of care including both active and inactive conservative therapies.
 - **Active Conservative Therapies** – Actions or activities that strengthen supporting muscle groups and target key spinal structures, including physical therapy, occupational therapy, physician supervised home exercise program (HEP), and/or chiropractic care.
 - **HEP** – A 6-week program requiring an exercise prescription and/or plan and a follow-up documented in the medical record after completion, or documentation of the inability to complete the HEP due to a stated physical reason (ie, increased pain, inability to physically perform exercises). Patient inconvenience or noncompliance without explanation does not constitute an inability to complete.

- **Inactive Conservative Therapies** – Passive activities by the patient that aid in treating symptoms associated with pain, including rest, ice, heat, medical devices, TENS use, and/or pharmacotherapy (prescription or over the counter [non-steroidal anti-inflammatory drugs, acetaminophen]).
 - **Transcutaneous Electrical Nerve Stimulator (TENS)** – A device that utilizes electrical current delivered through electrodes placed on the surface of the skin to decrease the patient’s perception of pain by inhibiting the transmission of afferent pain nerve impulses and/or stimulating the release of endorphins. Its use, frequency, duration, and start dates must be documented in the medical record to be considered part of conservative therapy during the period of prior authorization request.
- **Functional Disability** – Acquired difficulty in performing basic everyday tasks or more complex tasks needed for independent living.
- **Radiofrequency Ablation (RFA)** – Minimally invasive treatment modality that percutaneously introduces an electrode under fluoroscopic guidance to thermocoagulate medial branches of the dorsal spinal nerves.
- **Sacroiliac Joint (SIJ) Injections** – Corticosteroid and local anesthetic therapeutic injections into the SIJ to treat pain that has not responded to conservative therapies.

D. Policy

I. Sacroiliac Joint Injections

- A. Diagnostic injections: CareSource considers up to 2 diagnostic SIJ injections for the treatment of chronic low back pain medically necessary when **ALL** the following criteria are met:
 1. somatic or nonradicular low back and/or lower extremity pain experienced for at least 3 months
 2. severe pain (ie. at least a 6 out of 10 on pain scale) and tenderness located in the SIJ region that cause functional disability
 3. positive response to at least 3 SIJ pain provocation test (eg, distraction, compression, thigh thrust, Gaenslen’s, Patrick’s test/FABER test, sacral thrust)
 4. failure of conservative therapy, as evidenced by **ALL** the following:
 - a. documentation in the medical record of at least 6 weeks of active conservative therapy (as defined above) within the past 6 months OR inability to complete active conservative therapy due to contraindication, increase pain, or intolerance
 - b. documentation in the medical record of at least 6 weeks of inactive conservative therapy (as defined above) within the past 6 months
 5. if a second diagnostic injection is requested, at least 1 week has passed since the initial injection
- B. Therapeutic injections: CareSource considers therapeutic SIJ injections medically necessary when **ALL** the following criteria are met:
 1. most recent SIJ injection led to at least 75% pain relief and functional improvement
 2. member experiences return of severe pain or deterioration in function
 3. injection is used in conjunction with conservative therapy (as defined above)

The MEDICAL Policy Statement detailed above has received due consideration as defined in the MEDICAL Policy Statement Policy and is approved.

4. injection is repeated at a frequency of no greater than every 2 months
5. no more than 4 injections total (diagnostic and therapeutic) have been administered at the same site in the last 12 months.

C. Exclusions/Limitations:

1. Codes 64451 and 27096 may not be billed together (on the same date for the same side of the body). Only one code will be reimbursed.
2. Image guidance and/or injection of contrast is included in sacroiliac injection procedures and may not be billed separately.
3. If neural blockade is applied for different regions or different sides, injections are performed at least one week apart.
4. Pain management literature highlighting controlled studies of SIJ pain management has not demonstrated injections of the SIJ to be effective as a long-term management modality. Long-term continuation may be subject to medical necessity review.
5. Monitored anesthesia and conscious sedation are not medically necessary.
6. The use of SIJ injections for the treatment of pain as a result of Herpes Zoster is considered not medically necessary due to insufficient evidence demonstrating efficacy in the peer-reviewed published literature.

II. Radiofrequency Ablation of the SIJ

A. Initial radiofrequency ablation of the SIJ

1. Radiofrequency ablation is considered medically necessary when **ALL** the following have been met in the last 6 months:
 - a. The clinical criteria above for failed conservative therapy (I.A.4.a. and I.A.4.b.) has been met.
 - b. One diagnostic injection per joint to evaluate pain and attain therapeutic effect has been performed with a reported 75% or greater reduction in pain after injection.

B. Repeat radiofrequency ablation of the SIJ

1. Conservative therapy and diagnostic injections are not required if there has been a reduction in pain for at least 12 months or more from the initial RFA within the last 36 months.
2. When there has not been a repeat RFA in the last 36 months, a diagnostic injection is required.
3. A maximum of 1 RFA for SIJ pain per side per 12 months is considered medically necessary.

C. Exclusions/Limitations

1. The use of cooled RFA for SIJ-mediated low back pain is considered not medically necessary due to insufficient evidence demonstrating efficacy in the peer-reviewed published literature.
2. Pain management literature highlighting controlled studies of SIJ pain management has not demonstrated the effectiveness of RFA as a long-term management modality. Long-term continuation may be subject to medical necessity review.

III. Implantable Spinal Cord Stimulators

The MEDICAL Policy Statement detailed above has received due consideration as defined in the MEDICAL Policy Statement Policy and is approved.

Members with indwelling implanted spinal cord stimulators or pain pumps should have a device interrogation report submitted with medical records for a prior authorization request for proposed interventional pain injections. If a device is not functioning properly, an escalation in pain may warrant evaluation and management of the implanted device.

E. Conditions of Coverage
 NA

F. Related Policies/Rules
 NA

G. Review/Revision History

DATE		ACTION
Date Issued	09/13/2023	New policy, approved at Committee.
Date Revised	01/31/2024	Annual review: updated references and formatting, approved at Committee.
	01/29/2025	Review: updated references, approved at Committee.
	12/17/2025	Review: added pain level criteria, increased number of provocation test positives and updated references. Approved at Committee.
Date Effective	03/01/2026	
Date Archived		

H. References

1. Chou R, Deyo R, Friedly J, et al. Nonpharmacologic therapies for low back pain: a systematic review for an American College of Physicians clinical practice guideline. *Ann Intern Med.* 2017;166(7):493-505. doi:10.7326/M16-2459
2. Chou R, Cohen SP. Subacute and chronic low back pain: nonsurgical interventional treatment. UpToDate. Updated April 29, 2025. Accessed November 24, 2025. www.uptodate.com
3. Cine HS, Uysal E, Demirkol M, Cetin E. Under what conditions is the intra-articular steroid injection superior to nonsteroidal anti-inflammatory drugs for treating sacroiliac joint pain? *Eur Rev Med Pharmacol Sci.* 2023;27(21):10539-10546. doi:10.26355/eurrev_202311_34331
4. Jamjoom AM, Saeedi RJ, Jamjoom AB. Placebo effect of sham spine procedures in chronic low back pain: a systematic review. *J Pain Res.* 2021;14:3057-3065. doi:10.2147/JPR.S317697
5. Janapala RN, Knezevic E, Knezevic NN, et al. Systematic review and meta-analysis of effectiveness of therapeutic sacroiliac joint injections. *Pain Physician.* 2023;26:E413-E435. Accessed November 24, 2025. www.painphysicianjournal.com
6. Lee DW, Pritzlaff S, Jung MJ, et al. Latest evidence-based application for radiofrequency neurotomy (LEARN): best practice guidelines from the American Society of Pain and Neuroscience (ASPN). *J Pain Res.* 2021;14:2807-2831. doi:10.2147/JPR.S235665

The MEDICAL Policy Statement detailed above has received due consideration as defined in the MEDICAL Policy Statement Policy and is approved.

7. Liu Y, Suvithayasiri S, Kim JS. Comparative efficacy of clinical interventions for sacroiliac joint pain: systematic review and network meta-analysis with preliminary design of treatment algorithm. *Neurospine*. 2023 Sep;20(3):997-1010. doi: 10.14245/ns.2346586.293.
8. Manchikanti L, Kaye AD, Soin A, et al. Comprehensive evidence-based guidelines for facet joint interventions in the management of chronic spinal pain: American Society of Interventional Pain Physicians (ASIPP) guidelines facet joint interventions 2020 guidelines. *Pain Physician*. 2020;23(3S):S1-S127. Accessed November 24, 2025. www.painphysicianjournal.com
9. Sacroiliac Joint Injection: A-1048 (AC). MCG. 29th ed. Updated June 23, 2025. Accessed December 1, 2025. www.careweb.careguidelines.com
10. Sayed D, Grider J, Strand N, et al. The American Society of Pain and Neuroscience (ASPN) evidence-based clinical guidelines of interventional treatments for low back pain. *J Pain Res*. 2022;15:3728-3832. doi:10.2147/JPR.S386879
11. Szadek K, Cohen SP, de Andres Ares J, et al. Sacroiliac joint pain. *Pain Pract*. 2023;00:1-20. doi:10.1111/papr.13338
12. Wu L, Tafti D, Varacallo M. Sacroiliac joint injection. *StatPearls*. StatPearls Publishing; 2023. Updated August 4, 2023. Accessed November 24, 2025. www.ncbi.nlm.nih.gov

Independent Medical Review – January 2025